Ingenol 3,20-dibenzoate

Name: Ingenol 3,20-dibenzoate
Brand: MedChemExpress
SKU: HY-137295
Rating: 4.5 (1 reviews)

Cat. No.: HY-137295 Purity: 99.96%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells.

For research use only. We do not sell to patients.

Ingenol 3,20-dibenzoate Chemical Structure

CAS No. : 59086-90-7

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 702	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 702	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 638	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 1078	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 2090	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKC Isoform Specific Products:

View All Isoforms

PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
MT4	EC₅₀	27 nM Compound: 28	Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 25970561]
MT4	EC₅₀	9 nM Compound: 28	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 25970561]
Vero	EC₅₀	1.2 μM Compound: 28	Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days	[PMID: 25970561]

In Vitro

Ingenol 3,20-dibenzoate (0-10000 nM; 4 hours) enhanced NK cells (stimulated by A549 cells and H1299 cells) degranulation^[2].
Ingenol 3,20-dibenzoate (0.001-10 μg/ml) dose dependently promoted UT-7/EPO cell proliferation with an EC50 of 0.27 μg/ml (485 nM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ingenol 3,20-dibenzoate (20 μg/mouse; i.p.; on days 3, 7, and 11) lessens the anemia induced by 5-fluorouracil in an in vivo mouse model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (8–12 weeks old)^[3]
Dosage:	20 μg/mouse
Administration:	I.p.; On days 3, 7, and 11
Result:	Severity of 5-FU–induced anemia was lessened by IDB treatment on days 12 and 20.

Molecular Weight

556.65

Formula

C₃₄H₃₆O₇

CAS No.

59086-90-7

Appearance

Solid

Color

White to off-white

SMILES

O[C@]([C@H]1OC(C2=CC=CC=C2)=O)([C@@H](C(COC(C3=CC=CC=C3)=O)=C4)O)[C@]([C@@H]5C)(C=C1C)C([C@H]4[C@@](C(C)6C)([H])[C@@]6([H])C5)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (179.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7965 mL	8.9823 mL	17.9646 mL
5 mM	0.3593 mL	1.7965 mL	3.5929 mL
10 mM	0.1796 mL	0.8982 mL	1.7965 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (8.98 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (282 KB) SDS (393 KB)

COA (263 KB) RP-HPLC (243 KB)

Handling Instructions (2659 KB)

References

[1]. Asada A, et al. Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation. J Biol Chem. 1998;273(43):28392-28398. [Content Brief]

[2]. Gong C, et al. Enhancement of NK cell-mediated lysis of non-small lung cancer cells by nPKC activator, ingenol 3,20 dibenzoate. Mol Immunol. 2017;83:23-32. [Content Brief]

[3]. Oh JG, et al. Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses. Mol Pharmacol. 2015;88(2):392-400. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7965 mL	8.9823 mL	17.9646 mL	44.9115 mL
	5 mM	0.3593 mL	1.7965 mL	3.5929 mL	8.9823 mL
	10 mM	0.1796 mL	0.8982 mL	1.7965 mL	4.4912 mL
	15 mM	0.1198 mL	0.5988 mL	1.1976 mL	2.9941 mL
	20 mM	0.0898 mL	0.4491 mL	0.8982 mL	2.2456 mL
	25 mM	0.0719 mL	0.3593 mL	0.7186 mL	1.7965 mL
	30 mM	0.0599 mL	0.2994 mL	0.5988 mL	1.4971 mL
	40 mM	0.0449 mL	0.2246 mL	0.4491 mL	1.1228 mL
	50 mM	0.0359 mL	0.1796 mL	0.3593 mL	0.8982 mL
	60 mM	0.0299 mL	0.1497 mL	0.2994 mL	0.7485 mL
	80 mM	0.0225 mL	0.1123 mL	0.2246 mL	0.5614 mL
	100 mM	0.0180 mL	0.0898 mL	0.1796 mL	0.4491 mL